Figure 5.

AMPK activation by Canagliflozin protects VE-Cad integrity in HMECs challenged with human septic plasma. VE-Cad immunostainings performed on HMECs. HMECs were transfected with scramble or ⍺1AMPK targeting siRNA (50 nM) for 48 h, before being treated with canagliflozin (3 µM) or DMSO for one hour, then incubated with 10% plasma of (a) healthy volunteers (HV) or (b) septic shock patients (SS) for 30 min. Typical examples of pictures are shown. The experiment has been repeated with 4 different donors for each group (see Supplemental Fig. 2). Intercellular gaps are indicated by white arrows. Nuclei were stained with DAPI. Scale bar, 50 µm.